1197397-92-4 Usage
Uses
Used in Pharmaceutical Research:
6-[2-(Diethylamino)ethyl]-10,11-dihydro-1H-dicyclopenta[c,g]carbazole-3,9(2H,6H)-dione hydrochloride is used as a research compound for its anti-cancer properties, specifically targeting proteins and pathways that contribute to the development and progression of cancer. It is utilized in laboratories to investigate its efficacy and mechanism of action in inhibiting cancer cell growth.
Used in Oncology:
In the field of oncology, 6-[2-(Diethylamino)ethyl]-10,11-dihydro-1H-dicyclopenta[c,g]carbazole-3,9(2H,6H)-dione hydrochloride is used as a potential therapeutic agent for cancer treatment. Its application is based on its ability to interfere with the molecular mechanisms that drive cancer, offering a new avenue for the development of targeted cancer therapies.
Used in Drug Development:
6-[2-(Diethylamino)ethyl]-10,11-dihydro-1H-dicyclopenta[c,g]carbazole-3,9(2H,6H)-dione hydrochloride is also used in the development of new drugs for cancer treatment. Its unique structure and anti-cancer activity make it a valuable candidate for further research and potential incorporation into pharmaceutical formulations designed to combat various types of cancer.
Check Digit Verification of cas no
The CAS Registry Mumber 1197397-92-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,9,7,3,9 and 7 respectively; the second part has 2 digits, 9 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1197397-92:
(9*1)+(8*1)+(7*9)+(6*7)+(5*3)+(4*9)+(3*7)+(2*9)+(1*2)=214
214 % 10 = 4
So 1197397-92-4 is a valid CAS Registry Number.
1197397-92-4Relevant articles and documents
Carbazole compounds and therapeutic uses of the compounds
-
, (2015/09/28)
Compounds of the general structural formula (I) and (II) and use of the compounds and salts and hydrates thereof, as therapeutic agents are disclosed. Treatable diseases and conditions include cancers, inflammatory diseases and conditions, and immunodeficiency diseases. (I), (II).